A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2008-08-25
Target enrollment:
Participant gender:
Summary
This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter study to
evaluate the efficacy and safety of rituximab compared with placebo when combined with a
single stable background immunosuppressive medication in subjects with moderate to severe
systemic lupus erythematosus (SLE). The primary efficacy endpoint of the trial will be
evaluated at 52 weeks.